Drugs / BAY2327949
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04552262 | Sep → Dec 2020 | chronic kidney disease | Bayer | Terminated | No outcome recorded |
| Phase 1 | NCT04004195 | Jul 2019 → Feb 2020 | — | Bayer | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT04661917 | May 2021 → Apr 2022 | diabetic kidney disease | Bayer | Withdrawn | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BAY2327949 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04552262 ↗ |
| Action | Inhibit | “It works by binding to and blocking proteins that can regulate blood flow through the kidneys.” NCT04552262 ↗ |
| Route | Oral | “single oral dose” NCT04004195 ↗ |